PTPN11 and lung carcinoma: In a recent report, Tang et al.18 demonstrated that treatment of KRAS and EGFR-driven murine lung cancer models with a SHP2 inhibitor increased expression of chemokines that promoted infiltration of T and B cells, but also granulocyte myeloid derived suppressor cells (gMDSC’s) via CXCR1/2 ligands.